Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | Journal of Neuroinflammation

Fig. 5

From: Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor

Fig. 5

Levels of TNF-α and IL-1β measured in the media of cultured BV2 cells exposed to LPS (0.5 μg/ml) in the presence or absence of VCE-003.2 (5 μM). Values are means ± SEM of at least 4 independent experiments each performed in triplicate. Data were assessed by the one-way analysis of variance followed by the Student–Newman–Keuls test (**p < 0.01, ***p < 0.005 versus control cells (no treated with LPS); ###p < 0.005 versus cells treated with LPS)

Back to article page